FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to medicine, namely to psychiatry, and concerns the use of GABA-steroid antagonists for treating central nervous system disturbances. That is ensured by administration of compounds of the group of GABA-steroid antagonists exhibiting blocking action in relation to 3alpha-hydroxy-5alpha/beta-steroids practically without an antagonist effect on a receptor A of gamma-aminobutyric acid (GABA), and compounds having selective antagonist effect on said receptor.
EFFECT: invention provides treatment and/or prevention of CNS disturbances caused by action of 3alpha-hydroxy-5alpha/beta-steroid, as well as GABA-A overstimulation.
9 cl, 4 tbl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 3α-ETHYNYL, 3β-HYDROXY, 5α-PREGNAN-20-OXIME FOR USE IN TREATING CNS DISORDERS | 2016 |
|
RU2712786C2 |
| NEW STEROID COMPOUNDS SHOWING HIGHER WATER SOLUBILITY AND METABOLISM RESISTANCE, AND METHODS FOR PREPARING THEM | 2007 |
|
RU2458065C2 |
| STEROID COMPOUNDS (VARIANTS), PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF PATIENTS WITH NERVOUS DISORDERS (VARIANTS) AND METHOD OF ANESTHESIA INDUCTION IN ANIMAL | 1995 |
|
RU2176248C2 |
| NEUROACTIVE STEROIDS, PHARMACEUTICAL PREPARATION, METHOD OF TREATMENT AND PROPHYLAXIS OF DIFFERENT DISORDERS, METHOD OF SLEEP INDUCTION AND METHOD OF ANESTHESIA INDUCTION WITH THEIR USING, METHOD OF MODULATION OF COMPLEX RECEPTOR GABAA-CHLORIDE IONOPHORE | 1996 |
|
RU2194712C2 |
| ORGANIC COMPOUNDS | 2019 |
|
RU2809023C2 |
| PHARMACEUTICAL EMULSION CONTAINING BIOLOGICALLY ACTIVE STEROIDS AND METHOD OF EMULSION PREPARING | 1994 |
|
RU2141313C1 |
| CB1 RECEPTOR ANTAGONISTS | 2012 |
|
RU2593751C2 |
| NEUROACTIVE STEROID SOLUTIONS AND METHODS FOR ADMINISTRATION | 2016 |
|
RU2803464C2 |
| PHARMACEUTIC COMPOSITION, WHICH CONTAINS HYDROXYLATED NEBIVOLOL | 2006 |
|
RU2433823C2 |
| GLUCURONIDATED NEBIVOLOL METABOLITES | 2006 |
|
RU2413518C2 |
